Siemens Healthineers and Sysmex Corporation have initiated the separate distribution of their combined wide hemostasis testing solutions to laboratories across the United States and Europe. This move aims to provide healthcare providers with simplified access to leading hemostasis testing solutions, crucial for identifying and monitoring bleeding and clotting disorders in patients.
Siemens Healthineers has integrated the CN-3000/6000, CS-2500, CS-5100, and CA-600 series systems into its portfolio, catering to high-, mid-, and low-volume testing needs. These systems are designed to enhance testing efficiency and streamline workflows, whether used independently or integrated into lab automation. Integration with Siemens Healthineers’ Atellica Diagnostics IT products allows for centralized visibility and control over hemostasis testing processes, facilitating automatic management of repeat testing, integration of quality control processes, and improvement of key performance indicators such as turnaround time through built-in analytics. Additionally, these systems enable standardized results production across multiple lab locations, ensuring excellent result correlation.
Robert Stowers, Executive Vice President and Head of Specialty Lab Solutions Business for Diagnostics at Siemens Healthineers, highlighted the importance of maximum productivity in laboratories facing operational and staffing challenges. The collaboration with Sysmex aims to offer a proven portfolio of hemostasis testing instruments and assays, providing significant benefits to laboratories worldwide.
Siemens Healthineers and Sysmex have forged a strong partnership over 25 years, emerging as leading solution providers in the global hemostasis segment. In February 2023, they established a collaborative agreement to distribute their combined hemostasis portfolio under their respective company names, alongside their wider portfolios of products and services, with the goal of offering broader and more effective hemostasis laboratory solutions to customers globally.
